within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01E_SulfonamidesAndTrimethoprim.J01ED20_TrimethoprimAndSulfonamidesCombinationsEGTrimethoprimSulfamethoxazole;

model TrimethoprimAndSulfonamidesCombinationsEGTrimethoprimSulfamethoxazole
  extends Pharmacolibrary.Drugs.ATC.J.J01ED20;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01ED20</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This drug is a fixed combination of the antibiotics trimethoprim and sulfamethoxazole, commonly known as co-trimoxazole. It is primarily used to treat a variety of bacterial infections, including urinary tract infections, respiratory tract infections, gastrointestinal infections, and Pneumocystis jirovecii pneumonia. It remains an approved and commonly used antimicrobial combination worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for co-trimoxazole (trimethoprim 160 mg and sulfamethoxazole 800 mg) after single oral dosing in healthy adult volunteers (male and female, aged 18-50 years). Model parameters primarily refer to the trimethoprim component.</p><h4>References</h4><ol><li><p>Martinez, AE, et al., &amp; Erb, S (2020). Oral antibiotic therapy in people who inject drugs (PWID) with bacteraemia. <i>Swiss medical weekly</i> 150 w20259â€“None. DOI:<a href=&quot;https://doi.org/10.4414/smw.2020.20259&quot;>10.4414/smw.2020.20259</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32564343/&quot;>https://pubmed.ncbi.nlm.nih.gov/32564343</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TrimethoprimAndSulfonamidesCombinationsEGTrimethoprimSulfamethoxazole;
